These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3494802)

  • 1. Tumor-specific T-lymphocyte cytotoxicity enhanced by low dose of C. parvum.
    Lau BH; Wang-Cheng RM; Tosk J
    J Leukoc Biol; 1987 May; 41(5):407-11. PubMed ID: 3494802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Corynebacterium parvum prevents immunization to admixed irradiated tumor cells by a local process.
    Titus MJ; Bartlett GL; Kreider JW
    Int J Cancer; 1982 Jun; 29(6):699-705. PubMed ID: 7107070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active, specific immunotherapy of murine leukemia. II. Adjuvant effect of Corynebacterium parvum.
    Bartlett GL; Kreider JW
    Int J Cancer; 1979 Nov; 24(5):636-43. PubMed ID: 528079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effects of different strains of Corynebacterium parvum on natural cell-mediated cytotoxicity.
    Nasrallah AG; Gallagher MT; Priest EL; Trentin JJ
    Cancer Res; 1980 Nov; 40(11):4159-64. PubMed ID: 7471057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of cancer using Corynebacterium parvum: similarity of two preparations in four animal tumor models.
    Bartlett GL; Kreider JW; Purnell DM
    Cancer; 1980 Aug; 46(4):685-91. PubMed ID: 7397633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation of NK and ADCC by Corynebacterium parvum in acute myeloid leukaemia patients.
    Hokland P; Ellegaard J
    Leuk Res; 1985; 9(1):175-84. PubMed ID: 3857405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradoxical effects of immunopotentiators on tumors and tumor viruses.
    Morahan PS; Schuller GB; Snodgrass MJ; Kaplan AM
    J Infect Dis; 1976 Jun; 133 Suppl():A249-55. PubMed ID: 932503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on natural killer cell activity and the influence of Corynebacterium parvum on murine T-cell leukemogenesis induced by butylnitrosourea.
    Seidel HJ; Stolz W
    J Cancer Res Clin Oncol; 1984; 107(3):199-205. PubMed ID: 6610680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of prolonged Corynebacterium parvum and cyclophosphamide administration on the growth of established tumors.
    Fisher B; Wolmark N; Saffer E; Fisher ER
    Cancer; 1975 Jan; 35(1):134-43. PubMed ID: 1109767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. I. Variation in administration of both agents.
    Fisher B; Wolmark N; Rubin H; Saffer E
    J Natl Cancer Inst; 1975 Nov; 55(5):1147-53. PubMed ID: 1206740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of conditions allowing Corynebacterium parvum to cause either augmentation or inhibition of natural killer cell activity against tumor cells in mice.
    Ojo E; Haller O; Kimura A; Wigzell H
    Int J Cancer; 1978 Apr; 21(4):444-52. PubMed ID: 149772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human peripheral null lymphocytes. II. Producers of type-1 interferon upon stimulation with tumor cells, Herpes simplex virus and Corynebacterium parvum.
    Peter HH; Dallügge H; Zawatzky R; Euler S; Leibold W; Kirchner H
    Eur J Immunol; 1980 Jul; 10(7):547-55. PubMed ID: 6157543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of spontaneous AKR leukemia by multiple inoculations of Corynebacterium parvum.
    Check JH; Silverman GA; Dryden RL; Brady LW
    Cancer; 1979 Aug; 44(2):488-91. PubMed ID: 476565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice.
    Herberman RB; Holden HT; Ting CC; Lavrin DL; Kirchner H
    Cancer Res; 1976 Feb; 36(2 pt 2):615-21. PubMed ID: 56223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of purified cell walls from Corynebacterium parvum.
    Riveros-Moreno V; Bomford R; Scott MT
    J Natl Cancer Inst; 1978 Mar; 60(3):653-8. PubMed ID: 625069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings: Immunotherapy of Moloney sarcoma virus tumours in mice with Corynebacterium parvum.
    Hamilton DN; Bell PR
    Br J Surg; 1974 Apr; 61(4):321. PubMed ID: 4832648
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanism of decline of natural killer cell activity in Corynebacterium parvum-treated mice: inhibition by erythroblasts and Thy 1.2+ lymphocytes.
    Savary CA; Lotzová E
    J Natl Cancer Inst; 1987 Sep; 79(3):533-41. PubMed ID: 2887687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Corynebacterium parvum alone and in combination with adriamycin in experimental tumor systems.
    Houchens DP; Johnson RK; Ovejera A; Gaston MR; Goldin A
    Cancer Treat Rep; 1976 Jul; 60(7):823-8. PubMed ID: 1009517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corynebacterium parvum as an immunotherapeutic agent in an ovarian cancer model.
    Knapp RC; Berkowitz RS
    Am J Obstet Gynecol; 1977 Aug; 128(7):782-6. PubMed ID: 560124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.